Latest long-term debt for RGC: $130K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Regencell Bioscience Holdings (RGC) currently reports a long-term debt of $130K as of December 2025. In the prior-year period, the figure was $0. Use the charts on this page to explore Regencell Bioscience Holdings's long-term debt history and peer comparisons.
Regencell Bioscience Holdings's long-term debt changed from $0 to $130K (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Regencell Bioscience Holdings reported $130K in long-term debt as of December 2025. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current long-term debt of $130K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Regencell Bioscience Holdings, and consider following RGC for alerts when major investors trade the stock.
Regencell Bioscience Holdings is classified in the Healthcare sector. On long-term debt, it currently shows $130K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RGC with unrelated industries.